R87.69
Abnormal cytological findings in specimens from other female genital organs
Clinical Classification Guidelines
Inclusion Terms
- Abnormal cytological findings in specimens from female genital organs NOS
Excludes Type 1
- dysplasia of vulva (histologically confirmed) (N90.0-N90.3)
Medical Intelligence & Overview
ICD-10 code R87.69 pertains to abnormal cytological findings in specimens taken from female genital organs, excluding specific diagnoses. Cytology involves examining cells from the body to detect disease or abnormalities. When test results indicate unexpected or atypical cell structures in samples from the female reproductive system, this code may be used. These findings often come from Pap smears or other cell sampling procedures and are crucial in early detection of potential health issues, including precancerous changes or infections.
Causes & Symptoms
Clinical Causes: Cellular changes due to infections such as human papillomavirus (HPV) Inflammatory processes in the genital tract Benign or precancerous lesions Hormonal influences causing cellular alterations Previous radiation or treatments affecting cell health Sample contamination or collection artifacts
Key Symptoms: Abnormal Pap test results No symptoms; findings are often incidental Vaginal spotting or bleeding (in some cases) Unusual vaginal discharge Pelvic discomfort or pain (less commonly)
Diagnostic & Treatment
Diagnosis Path: Diagnosis generally involves cytological examination of specimens obtained from the female genital area, such as Pap smears or other cell collection methods. When laboratory analysis reveals atypical or abnormal cells, additional testing may be required. This can include repeat cytology, HPV testing, or molecular assays to further identify the nature of the cellular changes. In some cases, colposcopy or biopsy might be recommended for a more detailed assessment, especially if precancerous conditions are suspected.
Treatment Protocols: While specific treatment depends on the exact nature of the findings, management often involves close monitoring and follow-up testing. If precancerous changes or infections are identified, treatment options may include topical medications, excisional procedures, or other localized therapies. The goal is to address any abnormalities early to prevent progression to more serious conditions, such as cervical or other genital cancers. Patient counseling and regular screening are essential components of managing abnormal cytology findings.
Clinical Advice & FAQs
Billing Guidance
Is R87.69 a billable ICD-10 code?
Yes, R87.69 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report R87.69?
Clinical documentation must specify the nature of Abnormal cytological findings in specimens from other female genital organs and any associated comorbidities for accurate reporting.
Cite this Clinical Reference